



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Oncology*

**Manuscript NO:** 88063

**Title:** Scinderin promotes glioma cell migration and invasion via remodeling actin cytoskeleton

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 07641669

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** United States

**Author's Country/Territory:** China

**Manuscript submission date:** 2023-09-08

**Reviewer chosen by:** Yu-Lu Chen

**Reviewer accepted review:** 2023-10-04 14:30

**Reviewer performed review:** 2023-10-14 09:41

**Review time:** 9 Days and 19 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation

<b>Scientific significance of the conclusion in this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS

In this submitted manuscript, Lin et al. found the highly expressed scindrin in glioma and its therapeutic potential for glioma treatment. However, some important data were missing or lack in the current version. I suggest the author make a major revision before submitting back again. 1. The supporting figure(s) are missing, for example Figure S1 (Line 172) . 2. The author only compared the mRNA expression difference of BCIN. How about the BCIN protein level between glioma and normal tissue? 3. When knockdown a gene two different shRNA at least should be involved, but the author only used one. 4. The author should show the effectiveness and specificity of shRNA in the knockdown of target gene using western blotting. 5. In Figure 3C, the data are not consistent with the conclusion, in which knockdown of SCIN promotes the migration of U87 cells. 6. The scale bar should be added in Figure 2E, and the length of all the scale bars in the manuscript should be indicated in a clear way. 7. How does SCIN activate the RhoA/FAK axis? Could the author make more investigation or discussion.